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Abstract 
Background: Head and neck squamous cell carcinoma (HNSCC) is associated with 
tobacco use.  Still, most smokers do not develop HNSCC.  The mechanisms of varying 
susceptibility to HNSCC are poorly studied to date.  Tobacco metabolite research 
provides insight regarding the innate metabolism and excretion of carcinogens.   
 
Methods:  Smokers with HNSCC (cases) were compared to smokers without HNSCC 
(controls) in a matched cohort. The tobacco metabolites studied are: 1-hydroxypyrene 
(1-HOP), N’-nitrosonornicotine (NNN), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL).    
 
Results:  In 33 subjects, mean 1-HOP was 1.82 pmol/mg creatinine vs 1.08 pmol/mg 
creatinine (p=0.004) and mean NNN was 0.10 pmol/mg creatinine vs 0.04 pmol/mg 
creatinine (p=0.01) in cases and controls, respectively.  NNAL did not differ between 
groups. 
 
Conclusions:  Smokers with HNSCC have elevated urinary levels of 1-HOP and total 
NNN compared to matched controls suggesting an increased effective exposure to these 
carcinogens.  Tobacco constituent metabolites may be useful in understanding tobacco-
related carcinogenesis in HNSCC.  
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Introductory Summary 
Each year, 40,000 people in the US and 500,000 people worldwide are diagnosed 
with head and neck squamous cell carcinoma (HNSCC).  Despite progress in reducing 
tobacco exposure in some parts of the world, HNSCC related to tobacco use remains a 
significant problem.  The risk for HNSCC in smokers is approximately 10 times higher 
than that of never-smokers.  When considering all new presentations of HNSCC, 80-
90% are associated with tobacco and alcohol use.  While SCC of some head and neck 
subsites is decreasing in incidence, other subsites have seen an increase.   
Multiple carcinogens have been identified in tobacco-containing products.  The 
carcinogens most commonly associated with tobacco use are tobacco-specific 
nitrosamines.  These nitrosamines are formed from tobacco alkaloids during the curing 
and processing of tobacco.  The most carcinogenic of these are 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK) and N’-nitrosonornicotine (NNN).  NNK is associated 
with the development of lung and pancreatic cancer whereas NNN is associated with 
esophageal cancer.  Polycyclic aromatic hydrocarbons (PAH) represent a diverse group 
of carcinogenic compounds.  1-Hydroxypyrene (1-HOP) is a urinary metabolite of 
pyrene, which is always present in PAH mixtures.  Techniques have been developed to 
quantify amounts of NNN, 1-HOP and NNAL (a surrogate measure for NNK) in urine as 
well as formaldehyde- and acetaldehyde –DNA adducts in leukocytes.  These tobacco 
metabolites have been shown to readily distinguish between those who are exposed and 
unexposed to tobacco.   
This project aimed to address the differences between tobacco users with and 
without carcinoma by comparing their exposure to specific tobacco carcinogens.  The 
study subjects were patients with HNSCC and a history of tobacco use.  The control 
group was made up of tobacco users who do not have HNSCC.  Our results 
demonstrated higher levels of 1-HOP and NNN in those smokers who had developed a 
head and neck cancer. This is an important finding as this is the first study of this type to 
be done in patients with head and neck cancer. These findings may be applied in the 
clinical realm to help distinguish those smokers who are at the highest risk of developing 
head and neck cancer. Such data has the potential to dramatically impact future efforts 
at disease prevention and early detection. 
 
vi 
 
 
 
 
 
 
 
Introduction 
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 Squamous cell carcinoma of the head and neck (HNSCC) is one of many 
cancers that are strongly associated with tobacco use(1) (2, 3). The risk for HNSCC in 
smokers is approximately 10 times higher than that of never-smokers (4).  While tobacco 
cessation does reduce the risk of carcinoma, there are conflicting data as to whether a 
past smoker’s risk of carcinoma ever decreases to the level of a never-smoker (5).  
Alcohol enhances the risk of HNSCC in tobacco users but also acts as an individual risk 
factor (6).  When considering all new presentations of HNSCC, 80%-90% are associated 
with tobacco and alcohol use (6).    
 Although smoking is an important causal factor for HNSCC, only a fraction of 
lifelong smokers develop HNSCC over their lifetime.  This is evident given that the 
number of smokers in the United States is estimated at approximately 46 million while 
there are approximately 50,000 cases of HNSCC diagnosed per year(7-9).  The factors 
that account for the difference in susceptibility between smokers with and without 
HNSCC are poorly studied to date.  Some smokers may be inherently more susceptible 
to developing carcinoma due to patterns of tobacco use, individual intrinsic metabolism 
of carcinogens, or altered excretion.  Additionally, variability in individual immune 
competence can impact susceptibility to a variety of carcinomas, including those of the 
head and neck(10).   Identifying those smokers at greatest risk for HNSCC would have 
great benefit through targeted smoking cessation efforts and enhanced surveillance in 
addition to a greater understanding of carcinogenic pathways.    
 One approach to better understand the extent of exposure to tobacco 
carcinogens is through the investigation of tobacco carcinogen metabolites.  The inter-
individual variation in risk of smoking-related HNSCC may be determined in part by 
individual variability in the uptake and metabolism of tobacco carcinogens. Evaluation of 
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tobacco-related carcinogens and their metabolites can determine exposure and extent or 
pattern of metabolism and perhaps ultimately characterize important differences 
between smokers who develop HNSCC and smokers who do not.  Much of the work 
performed thus far on biomarkers of tobacco-related carcinogens and toxicants has 
addressed their role in the development of lung cancer.  This work helps to inform the 
study in patients who develop HNSCC.  There are >70 established carcinogens in 
cigarette smoke (11).  With regard to lung carcinoma, 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) and polycyclic aromatic hydrocarbons (PAH) are considered to be 
important causative agents.  Exposure to NNK results in metabolic conversion to 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), also a potent pulmonary carcinogen 
in rats (12).  Administration of NNK to rodents results in the development of lung and 
nasal tumors.  Furthermore, epidemiologic data in humans directly links NNAL to the risk 
of developing lung cancer(12, 13).  NNAL is glucuronidated in humans to produce a mixture 
of glucuronides, NNAL-Glucs(14). Although NNK itself is not detectable in human urine 
due to its extensive metabolism, both NNAL and NNALGlucs (the sum of which will be 
designated as total NNAL) can be readily quantified in human urine (15, 16).  
 Many polycyclic aromatic hydrocarbons (PAH) are potent locally acting 
carcinogens in laboratory animals(17).  The most extensively applied and reliable 
biomarker of PAH exposure is 1-hydroxypyrene (1-HOP). It is a urinary metabolite of 
pyrene, which is always present in PAH mixtures.  While 1-HOP is not tobacco specific, 
urinary levels are generally 2-3 times higher in smokers when compared to non-
smokers(16, 18, 19).  Another commonly studied member of the PAH class is 
benzo[a]pyrene (BaP).  BaP causes skin tumors when applied to the skin of different 
strains of mice, while subcutaneous injection produces malignant tumors at the injection 
site.  Intratracheal administration alone or mixed with particulates caused benign and 
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malignant tumors in hamsters.  Administration of BaP in the diet to mice and rats of 
different strains increased tumor responses in multiple organs including the esophagus 
and tongue(17).  Inhalation administration of BaP to hamsters caused dose-related 
increases in tumors of the upper respiratory tract, including nose, larynx and trachea, 
and upper digestive tract including pharynx, esophagus and forestomach.   
N’-Nitrosonornicotine (NNN) is thought to play a role in both esophageal and oral 
cancer(16).  It can be readily quantified in human urine by assaying for free, unchanged 
NNN plus its metabolite NNN-N-Gluc(20).  NNN and its metabolites are present in the 
urine of both smokers and smokeless tobacco users.  The level of urinary NNN is 
significantly higher in smokeless tobacco users when compared to smokers.  This 
finding is consistent with the relatively higher levels of tobacco-specific nitrosamines in 
smokeless tobacco(20).   
 This report describes a preliminary analysis of tobacco metabolites in patients 
with HNSCC.  A cohort of smokers with HNSCC has been identified and enrolled in a 
control-matched study to determine the significance of urinary NNAL, NNN and 1-HOP 
in this patient population. 
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Materials and Methods 
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Study population 
 Approval from the University of Minnesota Institutional Review Board was 
obtained.  Cases consisting of smokers with a new or previous diagnosis of HNSCC 
presenting to the Otolaryngology Clinic at the University of Minnesota from April 2009 to 
June 2011 were identified for enrollment. After obtaining consent, a tobacco and alcohol 
use questionnaire was administered. This questionnaire is comprehensive in nature and 
queries multiple aspects of all tobacco use (smokeless and smoked) and alcohol use 
including duration of use, current and previous rates of use, specific products used, 
attempted cessation methods and perceived obstacles to cessation.  Following 
completion of the questionnaire, the enrollees submitted a 10 mL urine and 10 mL blood 
sample. The urine samples were kept in a -20°C cooler until assays were performed. 
The blood samples were centrifuged to allow separation of the buffy coat and then kept 
at -20°C for future studies.   
 Controls consisted of smokers enrolled in the University of Minnesota Tobacco 
Research Programs for smoking intervention or biomarker studies.  These smokers were 
also given the tobacco and alcohol use questionnaire and submitted blood and urine for 
analysis as above.  Data on control smokers are kept in databases at the Tobacco 
Research Programs at the University of Minnesota. The control databases contain 
demographics and urinary metabolite levels at the time of enrollment in smoking 
intervention studies.  Cases and controls were matched on gender and cigarettes per 
day for purposes of analysis.  Alcohol consumption is known to be a risk factor for 
HNSCC but does not directly impact the tobacco related metabolites described in this 
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report. It must be noted, however, that ethanol has been shown to be an effective 
solvent that can increase absorption of carcinogenic substances (21).  However, this 
effect is measureable at ethanol concentrations much higher than that seen in the most 
conventional alcoholic beverages (in which the ethanol concentration is generally 15% or 
less).  It was therefore determined that alcohol intake in our study population would have 
little to no measureable effect on the urinary tobacco metabolites quantified here and 
subjects were not matched on levels of alcohol intake. 
 
Experimental Assays 
Total NNAL, total NNN, and 1-HOP were determined as described previously.  
Briefly, the assay for total NNAL in urine was performed by a modification of a previously 
published method (15). The method involves solid-phase extraction of urine with Chem-
Elute and Oasis MCX mixed mode cation exchange cartridges followed by quantification 
by gas chromatography with nitrosamine selective detection. The detection limit of NNAL 
was 0.04 pmol/mL. The intraday precision of the assay was 10.9% relative SD (RSD) 
and interday precision was 13.7% RSD (15, 22).  1-HOP was determined by HPLC with 
fluorescence detection, using [D9]1-HOP as internal standard.  Intraday and interday 
precision were less than 5% RSD(23, 24). 
For the analysis of total NNN(25-27), 2-ml urine samples were mixed with 
[13C6]NNN internal standard and treated with 10N NaOH to convert NNN-N-Gluc to 
NNN (26).  After the hydrolysis, the samples were adjusted to pH 6-8 and extracted with 
ethyl acetate, extracted on ChemElut cartridges, and further purified by mixed mode 
cation exchange and normal phase extraction as previously described(27).  The samples 
were analyzed by liquid chromatography (LC)-tandem mass spectrometry (MS/MS) with 
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selected reaction monitoring for m/z 178 → m/z 148 for NNN and m/z 184 → m/z 154 for 
[13C6]NNN.   
Urinary creatinine was assayed from the same urine sample to adjust for 
dilutional effects.  Urinary creatinine was assayed by Fairview-University Medical Center 
Diagnostic Laboratories (Minneapolis) with a Kodak Ektachem 500 chemistry analyzer. 
 
 
Statistical Analysis 
 Statistical analysis was performed with the t-test using Stata (College Station, 
TX) software with two-sided p values <0.05 considered significant.   Given that this is an 
analysis of pilot data, we sought to strengthen the analysis and conclusions by 
performing control matching using a 3:1 ratio of controls to cases.  This was performed 
in the analysis of NNAL and 1-HOP.  3:1 matching was performed to decrease the 
impact of any outlier values contained in the control dataset.  However, we do not 
currently have sufficient controls with NNN determined to allow a 3:1 match.  This was 
due to the nature of our control database.  This database represents an ongoing 
collection of specimens (blood, urine) from smokers recruited for smoking cessation 
research.  While NNAL and 1-HOP have been routinely assayed on these smokers for 
several years, NNN has been assayed in a consistent fashion only recently.  As a result, 
the database contains fewer subjects with NNN values determined when compared to 
NNAL and 1-HOP.  As a result, the analysis of NNN was done with a 1:1 matching ratio.  
The standard deviation in the control group for NNN was lower than that seen for 1-HOP 
and NNAL such that his did not significantly impact the power of this study.  The number 
8 
 
 
 
of subjects needed to obtain power of 80% with α=0.5 to detect a 50% increase in 
creatinine-adjusted metabolite level ranged from 15-21 for NNN, 1-HOP and NNAL.    
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Results 
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 This analysis is based on examination of the first 33 HNSCC cases enrolled in 
our study.  The demographics and distribution of the tumor subsites in the 33 HNSCC 
cases is shown in Table 1.  The cohort is made up of 26 males and 7 females, all of 
whom smoked cigarettes as their only tobacco product.  The range of cigarettes per day 
was 4-60.  All levels of urinary toxicant metabolites were adjusted for urinary creatinine 
level. 
 Of the 33 cases, we were able to quantify 1-HOP in 29, total NNAL in 29, and 
total NNN in 32.  During the early stages of enrollment, some urine samples were lost or 
smaller than necessary such that we were not able to have all 3 metabolites assayed in 
some cases.  For 1-HOP and total NNAL, we used a 3:1 matching ratio of controls to 
cases to strengthen the analysis. Given that we were able to obtain 27 matched controls 
for the NNN values (see statistical analysis above), our analysis of NNN is based on the 
27 cases with available matched controls.  Matching variables were gender and 
cigarettes per day.  The metabolites studied here are not influenced by alcohol 
consumption.   
 The results of the statistical analysis are shown in Table 2.  Levels of 1-HOP and 
NNN in cases were approximately 1.7-2.5 times higher than that seen in controls.  In the 
case of 1-HOP and NNN, this difference reached statistical significance (p=0.004 and 
p=0.01, respectively).  Levels of NNAL were not significantly different between case and 
control groups.  Figures 1-3 are scatterplots of the total 1-HOP, NNN and total NNAL 
values in cases and controls.    
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Discussion 
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 Tobacco is well known to be a source of multiple carcinogens. Chronic use of 
tobacco products is strongly linked with the development of multiple forms of 
carcinoma(2). The mucosal lining of the upper aerodigestive tract receives significant 
exposure to tobacco smoke as it is transmitted from the lips to the lungs. As a result, it is 
common to see a strong history of tobacco use in patients presenting with HNSCC. Still, 
a relatively small proportion of smokers go on to eventually develop head and neck 
cancer. One explanation for this may be variability in the uptake and processing of 
tobacco carcinogens and toxicants based on individual genetic differences and other 
factors among users. 
 This report represents the first investigation of tobacco-related carcinogens and 
their metabolites in smokers with HNSCC compared to smokers without HNSCC.  The 
results demonstrate intriguing differences in levels of carcinogen exposure between 
these two populations despite controlling for cigarette consumption.  1-HOP is 
significantly elevated in the HNSCC cases compared to controls.  This is notable in that 
a significant difference is seen in a relatively small sample size.  The results indicate that 
PAH-related carcinogenesis may be prominent for this disease.  This suggests an 
exciting path for further investigation as smokers with HNSCC may have an increased 
susceptibility to the effects of 1-HOP and other PAH, thus resulting in their developing 
HNSCC while other smokers do not.   The difference in susceptibility can be mediated 
by several mechanisms, one of which may be the previously described polymorphisms 
of CYP1A1, GSTM1 and GSTT1 enzymes that result in activation of PAH(28).  Therefore, 
the data presented here points us in the direction of investigating these polymorphisms 
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in tobacco induced HNSCC. Given that 1-HOP is elevated in the smokers with HNSCC 
in this study, investigation of other PAH compounds may be warranted.   
 Our data demonstrating elevated NNN in those smokers with HNSCC, compared 
to smokers without HNSCC, is interesting given that NNN has been shown to induce 
esophageal and nasal cavity tumors in rats(29).  Like the results for 1-HOP (above), NNN 
is present in higher levels in smokers with HNSCC compared to smokers without 
HNSCC when controlling for cigarette intake.  This may be due to differences at the 
molecular level relating to activation and/or excretion of NNN such that those smokers 
who are less able to detoxify this carcinogen are at increased risk for HNSCC.   
 Given the anatomic proximity and histological similarity of the esophagus to the 
upper aerodigestive tract, this finding would seem to be intuitive as it is reasonable to 
expect a similar mechanism of carcinogenesis in tumors of the esophagus and upper 
aerodigestive tract.  Animal studies suggest a prominent role for NNN in the 
development of a variety of cancers(30). NNN given in drinking water or by subcutaneous 
injection induces predominantly nasal tumors in rats(12).  The tumors induced include 
squamous cell carcinoma, rhabdomyosarcoma, olfactory neuroblatoma as well as 
papillomas.  Both the esophageal and nasal mucosa can metabolically activate NNN, 
and DNA adducts are detected in both tissues.  Those rats receiving NNN in drinking 
water only are more likely to develop esophageal tumors than those receiving 
subcutaneous injection.  This finding is hypothesized to be related to direct contact of 
NNN with the esophageal mucosa in those rats given the compound in drinking water.  
In smokers, urinary total NNN was found to be strongly associated with the risk of 
developing esophageal cancer in a prospective study based on a cohort of 18,244 
Chinese men in Shanghai, China(31).   In that study, urinary total NNN was measured in 
samples collected before diagnosis in 77 patients with esophageal cancer and 223 
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individually matched controls, all current smokers.  The levels of total NNN were 
significantly higher in cases as compared to controls.  Odds ratios (95% confidence 
intervals) of esophageal cancer for the 2nd and 3rd  tertiles of total NNN were 3.99 (1.25-
12.7) and 17.0 (3.99-72.8), respectively, compared to the 1st tertile after adjustment for 
urinary total NNAL, total cotinine, and smoking intensity and duration (Ptrend<0.001).  
These findings along with data from previous experimental studies strongly suggest a 
significant and unique role of NNN in esophageal carcinogenesis in humans.  This is 
consistent with the data presented here in that total NNN is elevated in smokers with 
HNSCC. 
 In this study, total NNAL did not differ between cases and controls.  This 
suggests a less significant role for NNK (precursor of NNAL) in the carcinogenic pathway 
of HNSCC.  On the other hand, total NNAL is associated with the risk of developing lung 
cancer.  A recent study by Church et al prospectively examined serum levels of total 
NNAL in smokers with and without lung cancer (32).  Prior to adjustment for confounders, 
the variables of age, duration of smoking and serum total NNAL were statistically 
significantly associated with the risk of lung cancer.  After logistic regression analysis, 
only age and total NNAL level remained statistically significant. A second recent study 
examined pre-diagnostic levels of tobacco metabolites and the risk of lung cancer in two 
prospective cohorts of cigarette smokers (13).  Patients with total urinary NNAL in the 
second and third tertiles had an increased risk of developing lung cancer (RR:1.43 and 
2.11 respectively).  When considering levels of cotinine in combination with total NNAL, 
an interesting result was observed.  Those subjects who were in the highest tertile of 
total NNAL and total cotinine had an 8.5-fold risk of developing lung cancer compared to 
smokers with a comparable smoking history but total cotinine and NNAL levels in the 
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lowest tertile.  Similar more extensive studies need to be conducted among individuals 
with HNSCC.   
 We are encouraged by the potential implications of the data presented here as it 
supports the identification of tobacco-related carcinogens that are most important in the 
development of HNSCC.  This information will be useful in targeting the metabolism of 
those specific carcinogens that are most responsible for HNSCC.  In this way,  the 
genetic polymorphisms that account for varying metabolism, and therefore varying 
degrees of risk for tobacco-induced HNSCC, may be identified.   Ultimately, this 
information has the potential to identify those who are at highest risk for developing 
tobacco-induced HNSCC.  It is our hope that, with further study of the metabolites 
investigated in this report, as well as additional metabolites and markers, we can 
eventually describe tobacco constituent metabolite profiles that indicate “standard risk” 
or "highest risk” for developing HNSCC.  Given that the assays performed in this study 
are relatively inexpensive, it is conceivable that they may eventually be utilized in 
screening for those smokers who are most likely to develop HNSCC.  Lastly, our data 
suggests an important difference between the carcinogenic pathways of HNSCC and 
lung carcinoma in that NNAL levels have been shown to indicate risk for lung carcinoma 
but were not elevated in our subjects with HNSCC.  This is consistent with 
carcinogenicity studies of orally administered NNK and NNAL in rats.    
The main limitation of our study is that it is that it is preliminary in nature and thus 
contains a small cohort. However, we feel that the potential implications of the data are 
nonetheless significant as discussed above.  An additional limitation is that, due to the 
small sample size, we were unable to perform an analysis based on tumor sub-site 
within the upper aerodigestive tract.  We anticipate performing this analysis as our 
cohort increases in size.   
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 In summary, we have presented the first report of urinary tobacco-related 
carcinogen metabolites in patients with head and neck cancer. This preliminary analysis 
has identified statistically significant differences between smokers with HNSCC and 
smokers without HNSCC. We now plan to study these metabolites in a larger group of 
subjects. We anticipate that further study along this line will improve our understanding 
of tobacco associated carcinogenesis in head and neck cancer and provide a potential 
opportunity for pre-diagnosis risk assessment and prevention. 
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Tables and Figures 
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Table 1 N (%)  
  
Male 26/33 (79) 
Female 7/33 (21) 
  
Tumor Subsite  
Nasopharyx 1/33 (3) 
 
Oropharynx 
 
11/33 (33) 
Larynx 11/33 (33) 
Hypopharynx 3/33 (9) 
Oral cavity 7/33  (21) 
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Table 2 Case  Control  p value 
    
n (1-HOP) 30 100  
1-HOP 
(pmol/mg 
creatinine)  
(+/- SE) 
1.82 (+/-.25) 1.08 (+/-.12) 0.004 
    
n (NNN) 27 27  
NNN (pmol/mg 
creatinine) 
0.10 (+/-.02) 0.04 (+/-.005) 0.014 
    
n (NNAL) 29 100  
NNAL 
(pmol/mg 
creatinine) 
(+/- SE) 
1.51(+/-.19) 1.68 (+/- .11) 0.48 
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Figure 1:  Scatterplot of 1-Hydroxypyrene in cases and controls 
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Figure 1: Scatterplot of 1-HOP in study and control subjects
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Figure 2:  Scatterplot of N’-Nitrosonornicotine in cases and controls 
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Figure 3:  Scatterplot of NNAL in cases and controls 
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